Salarius Pharmaceuticals Stock (NASDAQ:SLRX)
Previous Close
$1.55
52W Range
$1.35 - $7.60
50D Avg
$2.16
200D Avg
$3.86
Market Cap
$2.15M
Avg Vol (3M)
$2.47M
Beta
0.96
Div Yield
-
SLRX Company Profile
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.
SLRX Performance
Peer Comparison
Ticker | Company |
---|---|
GOVX | GeoVax Labs, Inc. |
MGTA | Dianthus Therapeutics, Inc. |
NTRB | Nutriband Inc. |
FRTX | Fresh Tracks Therapeutics, Inc. |
AXLA | Axcella Health Inc. |
MREO | Mereo BioPharma Group plc |
HSTO | Histogen Inc. |
SABS | SAB Biotherapeutics, Inc. |
ARTL | Artelo Biosciences, Inc. |
CRVS | Corvus Pharmaceuticals, Inc. |
FWBI | Entero Therapeutics, Inc. |
AKTX | Akari Therapeutics, Plc |
VCNX | Vaccinex, Inc. |
AFMD | Affimed N.V. |
PIRS | Pieris Pharmaceuticals, Inc. |
ALRN | Aileron Therapeutics, Inc. |